Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Clarivate’s Drugs to Watch in 2025 report ... Germany and Spain. Novo and Eli Lilly have been duking it out in the fields of diabetes and obesity in recent years, but Lilly has another ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

WASHINGTON — Eli Lilly's obesity drug Zepbound ... as well as losing weight. Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists.